GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of why does nobody talk about SELECT — 24 comments in the full submission. View in context.
330
c/trialwatch·submitted 1 year ago by u/rohan_steiner

why does nobody talk about SELECT

Paperbranch of 11 comments

Asking properly rather than in a comment on somebody else’s thread: why does nobody talk about SELECT. Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight. The discontinuation numbers were the most useful thing in the paper for me and they were in…

Read the full submission and all 24 comments →

This branch

11 comments, started 1 year ago
u/receptor_bias_rick49 points·1 year ago

On means, which this board treats as targets and which are nothing of the sort.

A reported mean body weight change is the centre of a distribution that in these trials is very wide. Substantial numbers of participants did much better, and substantial numbers did considerably worse while remaining on the drug and in the analysis.

Quoting the mean as an expectation therefore misleads in both directions: it makes ordinary results look like failures and it makes exceptional results look normal. If a paper publishes the distribution — and several do, in the appendix — look at that instead. It is far more informative than the number in the abstract.

replysharereportpermalink
u/careful_gradient_again13 points·1 year ago

What was the discontinuation rate?

replysharereportpermalink
u/curious_panel_only9 points·1 year ago

check who the comparator was before you compare anything

replysharereportpermalink
u/first_hundred20 points·1 year ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/customs_seizure_sid16 points·1 year ago

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
u/yusuf_ramos5 points·1 year ago

phase 2 finds a dose, phase 3 measures the effect

replysharereportpermalink
u/ewan_tulloch1 point·1 year ago

the confidence interval is the finding, the point estimate is the headline

replysharereportpermalink
u/foam_head_fred15 points·1 year ago

What was the discontinuation rate?

careful_gradient_again is right about the programme names. They are different populations with different endpoints.

replysharereportpermalink
u/rina_sobczak7 points·1 year ago·edited

What was the comparator?

replysharereportpermalink
u/zaid_roos12 points·1 year ago·edited

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

replysharereportpermalink
u/bastian_ekstrom3 points·1 year ago·edited

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.